Screening of an FDA-approved compound library identifies apigenin for the treatment of myocardial injury

Apigenin is the active ingredient in Ludangshen. Although previous studies reported the cardioprotective actions of apigenin against doxorubicin (Dox)-induced cardiomyopathy, the underlying mechanisms remain incompletely understood. Since apigenin beneficially regulates various aspects of mitochondr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Haixia, Chen, Dong, Zhang, Xiaoqin, Chen, Mingxian, Zhi, Yinghao, Cui, Weilu, Li, Shanshan, Xu, Fan, Tan, Ying, Zhou, Hao, Chang, Xing, Chen, Hengwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620826/
https://www.ncbi.nlm.nih.gov/pubmed/37928261
http://dx.doi.org/10.7150/ijbs.85204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620826/
https://www.ncbi.nlm.nih.gov/pubmed/37928261
http://dx.doi.org/10.7150/ijbs.85204

Ejemplares similares